Investor MFN Partners Management, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by MFN Partners Management, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-02-12 13G/A 2,427,677 0
2021-03-15 13G/A US34431F1049 / Foley Trasimene Acquisition Corp 5,000,000
2021-02-12 13G / Foley Trasimene Acquisition Corp. II Units, each consisting of one share of Class A common stock, an 0
2021-02-12 13G CYCN / Cyclerion Therapeutics, Inc. 1,487,874 2,427,677
2021-02-12 13G 34431F103 / Foley Trasimene Acquisition Corp. 12,000,000 14,000,000
2020-08-27 13G / Foley Trasimene Acquisition Corp. II 10,000,000
2020-07-22 13G/A ACRS / Aclaris Therapeutics, Inc. 4,000,000 1,895,677
2020-07-10 13G/A 34431F103 / Foley Trasimene Acquisition Corp. 12,000,000
2020-07-10 13G/A 34431F103 / Foley Trasimene Acquisition Corp. 10,000,000 12,000,000
2020-06-05 13G 34431F103 / Foley Trasimene Acquisition Corp. 10,000,000
2020-02-13 13G/A ACRS / Aclaris Therapeutics, Inc. 4,000,000 4,000,000
2020-02-13 13G/A CYCN / Cyclerion Therapeutics, Inc. 1,506,852 1,487,874
2019-10-31 13G ACRS / Aclaris Therapeutics, Inc. 4,000,000
2019-04-11 13G CYCN / Cyclerion Therapeutics, Inc. 1,506,852